HIGH DOSE OF INTRAVAGINAL METRONIDAZOLE: EFFECTS IN THE PREVENTION OF RECURRENT BACTERIAL VAGINOSIS

Not Applicable

• Conditions: -N760 Acute vaginitis; Acute vaginitis; N760

• Registration Number: PER-083-07
• Lead Sponsor: IVERSIDAD PERUANA CAYETANO HEREDIA,

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2007-11-30
• Last Update Posted: 4 September 2023

Recruitment & Eligibility

• Status: Complete
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

• Women between 18-40 years of age.
• Abnormal vaginal discharge or bad-odor.
• Quick positive test (QuickVue Advance).
• Ability to provide informed consent.

Exclusion Criteria

• Women who report diabetes or immunosuppression.
• Women who report symptoms of pregnancy, including loss of menstruation for a period greater than 7 days, or positive pregnancy test.
• Women who have had a birth in the last 90 days.
• Women who have had an abortion during the past 30 days.
• Women who are menstruating or breastfeeding.
• Oral or intravaginal medications for vaginal discharge during the last 2 weeks.
• Inability to attend the follow-up visit one month after treatment ends.
• Women with mucopurulent cervical discharge or vaginal bleeding.
• Women with signs of pelvic inflammatory disease (eg, painful attachments or pain to cervical mobilization).
• Women with ovarian and uterine masses on physical examination.
• Women with severe abdominal pain.
• Women who are taking cimetidine, phenytoin or coumadin.

Study & Design

• Study Type: Interventional
• Study Design: Not specified